These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22146025)

  • 21. Benign prostatic hyperplasia: caveat for finasteride should be discussed before prescribing.
    Ammar H; Malani AK; Gupta C
    BMJ; 2006 Sep; 333(7569):654; author reply 654. PubMed ID: 16990336
    [No Abstract]   [Full Text] [Related]  

  • 22. Do no harm: a case in point.
    Justman S
    Perspect Biol Med; 2012; 55(2):291-8. PubMed ID: 22643765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dutasteride: high-grade prostate cancer. Risky in prostate cancer prevention.
    Prescrire Int; 2011 Nov; 20(121):267. PubMed ID: 22066315
    [No Abstract]   [Full Text] [Related]  

  • 27. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring the importance of PSA velocity.
    Tuma RS
    J Natl Cancer Inst; 2011 Mar; 103(6):454-61. PubMed ID: 21393606
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemoprevention of prostate cancer.
    Stephenson AJ; Abouassaly R; Klein EA
    Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoprevention of prostate cancer.
    Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Klein EA
    J Urol; 2009 Aug; 182(2):499-507; discussion 508. PubMed ID: 19524966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Screening for prostate cancer--what does the evidence show?].
    Borre M; Iversen P
    Ugeskr Laeger; 2007 May; 169(20):1887-8. PubMed ID: 17553362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP; Hessels D; Peelen WP; Vergunst H; Mulders PF; Schalken JA
    Prostate; 2009 Nov; 69(15):1624-34. PubMed ID: 19588525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J; Altwein J
    Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of PSA as biomarker in nutritional intervention studies of prostate cancer.
    van Weerden WM; Schröder FH
    Chem Biol Interact; 2008 Jan; 171(2):204-11. PubMed ID: 18177847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can we stop ordering prostate-specific antigen screening tests?
    Katz MH
    JAMA Intern Med; 2013 May; 173(10):847-8. PubMed ID: 23588841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.